Status:
UNKNOWN
Antibodies Responses to COVID-19 Infection in Hospitalized Patients
Lead Sponsor:
Imam Abdulrahman Bin Faisal University
Collaborating Sponsors:
Dammam Medical Complex
Institute for Research and medical consultations (IRMC)
Conditions:
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection)
Hospitalized Patients
Eligibility:
All Genders
18+ years
Brief Summary
1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd...
Detailed Description
1.1. Prevalence of Coronavirus infection: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused an ongoing pandemic where the first case was reported in Wuhan china earlie...
Eligibility Criteria
Inclusion
- Symptomatic infection with at least 2 weeks' time interval since the symptom's onset.
- Laboratory-confirmed COVID-19 with positive SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) testing of nasopharyngeal or oropharyngeal swabs.
- Inpatients in either isolated wards or ICU.
- Agreement for blood sampling during the course of the study.
Exclusion
- Decline consent to participate.
- Pregnancy.
- Asymptomatic patients, who are PCR positive during routine screening upon admission
- Administration of immunoglobulins within the 3 proceeding months including Covid-19 convalescent plasma.
- Patients with Don't resuscitate orders
- Patients with terminal illnesses regardless of the severity of SARS-CoV 2 infection.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2021
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT04520880
Start Date
August 1 2020
End Date
February 1 2021
Last Update
August 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imam Abdulrahman Bin Faisal University
Dammam, Eastern Province, Saudi Arabia, 31952